Chair-to-lab workflow for oral brush biopsy · Illustrative demo on sample datahello@brushbiopsy.com
BrushBiopsy
The package

Acquire BrushBiopsy.

The product, the code and the development and tech support team are offered together. Meet the development and tech support team on your introduction call. They stay with the product after the sale, ready to back your five-year roadmap.

Five-part package

What is included.

1

The domain

brushbiopsy.com, the exact-match name for the category.

2

The website

This product site with recreated product screens, brand, offer handling, analytics and privacy plumbing.

3

The idea and 3-year roadmap

An open, lab-neutral rail for oral brush biopsy, with a cervical self-sample module in Year 3.

4

The working MVP

A chair-to-lab demo at /demo: order, chain of custody, reader triage, sign-off, report and recall. Sample data only.

5

Five-year financials

Illustrative projections below, built only from the assumptions stated on this page.

  • Working MVP: kit orders, chain-of-custody tracking, triage queue, reader sign-off, report and recall register on sample data
  • Lab-neutral by design: any accredited cytology laboratory can join
  • Regulatory wedge: the workflow layer ships first; the AI prioritisation module follows through formal submissions
  • Clear path to a cervical self-sample triage module in Year 3
Five-year plan

Illustrative projections

Illustrative projections, not a forecast or guarantee. BrushBiopsy has no operating history, customers or revenue. Illustrative projections, not a forecast or guarantee. Built only from the assumptions stated here; not actual results.

IllustrativeY1Y2Y3Y4Y5
Customers (year end)62460120210
New customers6183865100
Blended revenue per customer$36k$39k$42k$45k$49k
Revenue$108k$583k$1.8M$4.1M$8.1M
Gross margin60%67%73%77%80%
Sales and marketing$84k$252k$532k$910k$1.4M
R&D, quality, regulatory, G&A$1.0M$1.6M$2.3M$3.1M$4.0M
EBITDA−$1.0M−$1.5M−$1.5M−$867k$1.1M

Assumptions

  • A customer is a dental group or dental support organisation, an independent cytology laboratory, or a regional screening programme. Blended annual revenue of $36k per customer in Year 1 (platform subscription plus a per-sample workflow fee), rising 8% a year as more sites and sample volume are covered.
  • New customers: 6, 18, 38, 65 and 100 in Years 1 to 5, starting with UK and US dental groups that already bill brush biopsies (CDT D7288 in the US) and one partner laboratory per region.
  • 8% annual logo churn. Customer acquisition cost of $14k per new customer, led by a chair-to-lab pilot rather than field sales.
  • Gross margin rises from 60% to 80% as courier, kit and hosting costs are spread over volume. Laboratory reading is performed and billed by partner laboratories, not by BrushBiopsy.
  • R&D, quality, regulatory and G&A budget of $1.0M rising to $4.0M by Year 5, including the cost of regulatory submissions for the AI module. No outside funding is assumed or implied.

Method: revenue = average customers in the year × blended revenue per customer; customers at year end = start × (1 − 8% churn) + new customers; operating costs = new customers × acquisition cost + the stated fixed budget.

Market context (published figures, not part of the model)

Roadmap

Years 1 to 3.

Year 1

The rail

  • Kit ordering, barcode chain of custody and courier tracking for dental groups
  • Partner-lab triage queue with structured reporting and reader sign-off
  • Recall register for atypical results, with referral and histology closure
Year 2

The reader

  • Whole-slide image viewer with AI-assisted cell prioritisation, validated with partner labs
  • Regulatory submissions planned (US De Novo/510(k), UKCA, IVDR) before any clinical use of the AI module
  • Practice-management and lab-system integrations
Year 3

The network

  • Multi-lab network across the UK, US and one high-burden region
  • Cervical self-sample triage module for HPV-positive follow-up
  • Outcome dataset (brush result versus histology) for payers and guideline bodies
For diligence

Risks a serious buyer should weigh.

Clinical evidence
Published brush-biopsy accuracy varies widely and payers do not treat it as a substitute for scalpel biopsy. The product must stay positioned as workflow and decision support.
Regulation
The AI prioritisation module is a regulated IVD in the US, UK and EU. Submissions take time and money, and are budgeted in the plan's fixed costs.
Lab partnerships
The model depends on accredited partner laboratories. Each region needs at least one before practices can be signed.
Incumbent response
The incumbent closed-lab provider could open its own network or tooling.
Data protection
Health data requires UK GDPR, DSPT and HIPAA controls before any live pilot.
Not a diagnostic device

Illustrative product demo only. BrushBiopsy as shown here is not a medical device, is not cleared or approved by any regulator, and does not diagnose, screen for or rule out any disease. All screens use fictional sample data. Clinical decisions must be made by qualified professionals using validated, regulated tests.